Back to Search
Start Over
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib
- Source :
- Cancer Immunology Research, Cancer Immunology Research, 2017, 5 (7), pp.582-593. ⟨10.1158/2326-6066.CIR-16-0380⟩, Cancer Immunology Research, American Association for Cancer Research, 2017, 5 (7), pp.582-593. ⟨10.1158/2326-6066.CIR-16-0380⟩, Cancer Immunology Research-Cancer Immunol Res, Cancer Immunology Research-Cancer Immunol Res, Philadelphia, PA : American Association for Cancer Research, [2013]-, 2017, 5 (7), pp.582-593. 〈10.1158/2326-6066.CIR-16-0380〉
- Publication Year :
- 2017
- Publisher :
- American Association for Cancer Research (AACR), 2017.
-
Abstract
- Over 60% of human melanoma tumors bear a mutation in the BRAF gene. The most frequent mutation is a substitution at codon 600 (V600E), leading to a constitutively active BRAF and overactivation of the MAPK pathway. Patients harboring mutated BRAF respond to kinase inhibitors such as vemurafenib. However, these responses are transient, and relapses are frequent. Melanoma cells are efficiently lysed by activated natural killer (NK) cells. Melanoma cells express several stress-induced ligands that are recognized by activating NK-cell receptors. We have investigated the effect of vemurafenib on the immunogenicity of seven BRAF-mutated melanoma cells to NK cells and on their growth and sensitivity to NK-cell–mediated lysis. We showed that vemurafenib treatment modulated expression of ligands for two activating NK receptors, increasing expression of B7-H6, a ligand for NKp30, and decreasing expression of MICA and ULBP2, ligands for NKG2D. Vemurafenib also increased expression of HLA class I and HLA-E molecules, likely leading to higher engagement of inhibitory receptors (KIRs and NKG2A, respectively), and decreased lysis of vemurafenib-treated melanoma cell lines by cytokine-activated NK cells. Finally, we showed that whereas batimastat (a broad-spectrum matrix metalloprotease inhibitor) increased cell surface ULBP2 by reducing its shedding, vemurafenib lowered soluble ULBP2, indicating that BRAF signal inhibition diminished expression of both cell-surface and soluble forms of NKG2D ligands. Vemurafenib, inhibiting BRAF signaling, shifted the balance of activatory and inhibitory NK ligands on melanoma cells and displayed immunoregulatory effects on NK-cell functional activities. Cancer Immunol Res; 5(7); 582–93. ©2017 AACR.
- Subjects :
- 0301 basic medicine
MAPK/ERK pathway
Cancer Research
NK Cell Lectin-Like Receptor Subfamily K
Melanoma
Immunology
[SDV.CAN]Life Sciences [q-bio]/Cancer
Biology
Natural killer T cell
NKG2D
medicine.disease
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
3. Good health
03 medical and health sciences
030104 developmental biology
[SDV.CAN] Life Sciences [q-bio]/Cancer
Cancer research
medicine
Receptor
Vemurafenib
neoplasms
V600E
medicine.drug
Subjects
Details
- ISSN :
- 23266074 and 23266066
- Volume :
- 5
- Database :
- OpenAIRE
- Journal :
- Cancer Immunology Research
- Accession number :
- edsair.doi.dedup.....a14c73dd5cd78f986560f4d79ef301f6